2026 organic growth guided at 2-3% with multiple upside paths
Revvity beat Q4 expectations with 4% organic growth and $1.70 EPS, driven by strong diagnostics and improved life sciences trends. Management guides 2026 to 2-3% organic growth and EPS of $5.35-$5.45, remaining cautious but optimistic about a potential gradual end-market recovery. Q4 revenue of $772M with 4% organic growth; EPS of $1.70 beat by $0.06.
Buzzberg read2026 organic growth guided at 2-3% with multiple upside pathsRevvity beat Q4 expectations with 4% organic growth and $1.70 EPS, driven by strong diagnostics and improved life sciences trends. Management guides 2026 to 2-3% organic growth and EPS of $5.35-$5.45, remaining cautious but optimistic about a potential gradual end-market recovery. Q4 revenue of $772M with 4% organic growth; EPS of $1.70 beat by $0.06.Read full analysisCollapse analysis
Revvity beat Q4 expectations with 4% organic growth and $1.70 EPS, driven by strong diagnostics and improved life sciences trends. Management guides 2026 to 2-3% organic growth and EPS of $5.35-$5.45, remaining cautious but optimistic about a potential gradual end-market recovery. Q4 revenue of $772M with 4% organic growth; EPS of $1.70 beat by $0.06.
Diagnostics grew 7% organically in Q4; Life Sciences was flat with improving instrument demand.
Expects margin expansion to 28% operating margin in 2026, with a dip to 23% in Q1.
Revenue$0.7721B
reported
EPS$1.70
reported
Gross margin43.8%
reported
Op margin14.47%
reported
What changed this quarter
01
Guidance
2026 organic growth guided at 2-3% with multiple upside paths
Guidance · revenue to $2.975B
02
AI
Signals Synthetica AI platform launched with Lilly collaboration
Management highlighted the launch of Signals Synthetica AI models-as-a-service platform and a collaboration with Lilly TuneLab, positioning the Signals software business to capitalize on AI-driven drug discovery. They expect the platform to accelerate drug development timelines…
03
Demand
Life sciences instruments show first sequential improvement in years
Management acknowledges improving end-market signals but maintains a prudent 2026 outlook, emphasizing that recent improvements are 'only recent' and they remain 'cognizant' of a fluid environment.
04
Buybacks
Share buybacks reduced share count by 12% since 2023
Management highlighted the launch of Signals Synthetica AI models-as-a-service platform and a collaboration with Lilly TuneLab, positioning the Signals software business to capitalize on AI-driven drug discovery. They expect the platform to accelerate drug development timelines and see potential for revenue growth, though no material benefit from these launches is embedded in 2026 guidance.
Demand
Bookings & conversion
Life sciences instruments show first sequential improvement in years. Management acknowledges improving end-market signals but maintains a prudent 2026 outlook, emphasizing that recent improvements are 'only recent' and they remain 'cognizant' of a fluid environment.
Capex
Investment and capacity
Capex is not explicitly discussed. Management focuses on cost efficiency initiatives, including footprint consolidations and supply chain synergies, expected to be completed by end of Q2 2026, supporting margin expansion.
Tone · Cautiously Optimisti
Management acknowledges improving end-market signals but maintains a prudent 2026 outlook, emphasizing that recent improvements are 'only recent' and they remain 'cognizant' of a fluid environment.
Supply-chain alpha
A1
Life sciences instruments saw a strong double-digit sequential revenue increase from Q3 to Q4 2025 and were roughly flat year-over-year, marking a meaningful improvement versus the significant declines seen over the prior three years.
“We also saw continued improvements in demand for our life sciences instruments during the fourth quarter as they were also roughly flat on a year over year basis. This performance for our instruments represented a strong double-digit seque…”
The company saw pharma customer organic growth of low single digits and academic/government decline of low single digits in Q4, with no budget flush observed, indicating the pharma recovery is still in early, cautious stages.
“I would say that overall, what we've seen is cautious optimism and consistency in terms of order trending i wouldn't say that there was a budget flush i think that's the way i would think of it”
The firm is assuming China immunodiagnostics will decline slightly in the second half of 2026, retracting a previous expectation of a return to growth, though no fundamental market changes have occurred.
“I would say we are no longer forecasting a return to low single digit growth in the second half of the year. We expect it to now be, I would say, down slightly in the second half of the year.”
Management is highlighting a major partnership with Lilly to co-fund access to its Signals platform and provide AI modeling credits, which could drive adoption and engagement.
“As part of our Zynthetica launch, we also announced our important collaboration with Lilly and its TuneLab initiative. Lilly TuneLab's AI models are built on knowledge and insight from over a billion dollars of R&D investment by the”
… these AI models will be used by scientists to more quickly iterate and improve their drug candidates and development, both in the wet lab and virtually, enabling a lab-in-the-loop approach to drug development. We expect this repeating loop of faster and more frequent refinement and advancements of drugs and development will ultimately accelerate drug development timelines versus previous methods. As part of our Zynthetica launch, we also announced our important collaboration with Lilly and its TuneLab initiative. Lilly TuneLab's AI models are built on knowledge and insight from over a billion dollars of R&D investment by the company over the last decade. Lilly is not only making these models available to smaller biotechs in exchange for them sharing data back into the platform, but they are also co-funding with us access to our signals platform and providing Synthetica modeling credits to biotech users. exemplifying our shared commitment to driving adoption and engagement of both platforms. Signals is embedded in nearly all major pharma companies around the world already. And now with Synthetica and our collaboration with Lily Tune Lab, we can uniquely deliver functional AI …
Life sciences instruments saw a strong double-digit sequential revenue increase from Q3 to Q4 2025 and were roughly flat year-over-year, marking a meaningful improvement versus the significant declines seen over the prior three years. — OES demand is showing signs of stabilization and potential recovery, which is a leading indicator for the broader life sciences tools sector.
“We also saw continued improvements in demand for our life sciences instruments during the fourth quarter as they were also roughly flat on a year over year basis. This performance for our instruments represented a strong double-digit”
… growth was flat year over year with positive low single digit growth from our pharma customers and a low single digit year-over-year decline in sales from our academic and government customers which included a modest headwind from the us government shutdown importantly Our sales of life sciences reagents and consumables were a bit better than we had expected and were flat year over year overall. We also saw continued improvements in demand for our life sciences instruments during the fourth quarter as they were also roughly flat on a year over year basis. This performance for our instruments represented a strong double-digit sequential increase in total revenue as compared to the third quarter and marked a meaningful organic growth improvement compared to the more significant declines we've seen with these products fairly consistently over the past three years. Given the strong finish to 2025 and the progress we've made over the past few years, we chose to reinvest a portion of this operating upside back into the company during the fourth quarter. With a particular focus on supporting our employees who have remained highly dedicated and productive throughout the year. This …
The company saw pharma customer organic growth of low single digits and academic/government decline of low single digits in Q4, with no budget flush observed, indicating the pharma recovery is still in early, cautious stages. — Improvement is based on policy clarity, not a burst of year-end spending, suggesting a slower, more durable recovery rather than a sharp snapback.